Polaris Market Research presents its latest market research report, titled Minimal Residual Disease (MRD) Market Size, Share, Trends & Forecast, 2026-2034. It is a comprehensive market research report analyzing the fast-evolving minimal residual disease (MRD) market. The report offers insight into the current market landscape, drivers for growth, emerging trends, competitive dynamics, and future scope for growth. The study is a combination of qualitative and quantitative analysis, giving insights about the size of the market, segments, regional performance, and industry developments. By going through the report, stakeholders can get an in-depth overview of the minimal residual disease (MRD) market and its outlook during the forecast period.

Minimal Residual Disease (MRD) Market Key Takeaways

• The minimal residual disease market size was valued at USD 2.38 billion in 2025.
• The market is estimated to reach USD 7.20 billion by 2034.
• The market is projected to witness a CAGR of 13.1% from 2026 to 2034.
• The leukemia detection-target segment held 38.6% of the market share in 2025.
• The solid tumors segment is likely to grow at 12.4% CAGR during the forecast period.
• The North America region held 45.7% of market share in 2025.
• The Asia Pacific region is expected to grow at a 15.2% CAGR from 2026 to 2034.

What is Minimal Residual Disease (MRD) Market?

The minimal residual disease (MRD) market covers highly sensitive testing technologies, including NGS, PCR, and flow cytometry, used to detect trace cancer cells remaining after treatment. Widely applied in leukemia, lymphoma, and multiple myeloma monitoring, MRD testing supports precision oncology and relapse prediction, driving market growth and expanding market share among key players worldwide, per the industry report's market forecast.

Market Dynamics

The report examines the key market dynamics influencing the growth and development of the minimal residual disease (MRD) market. It analyzes the market drivers, market opportunities, market trends, and restraints that might impact the growth of the market.

Key Market Driver: Rise in Cancer Cases

Global cancer incidence continues to climb, directly expanding the population eligible for minimal residual disease monitoring. According to the American Association for Cancer Research, approximately 18.6 million cancer survivors were living in the U.S. alone as of January 2025. As patients undergoing therapy increasingly require precise post-treatment surveillance, and as traditional methods such as PCR, FISH, and flow cytometry struggle to detect residual cells at extremely low thresholds, demand for advanced MRD testing technologies is rising, supporting sustained market size expansion through the forecast period.

Market Opportunity: Liquid Biopsy Expansion into Solid Tumors

MRD testing has traditionally centered on blood cancers, but researchers are increasingly adapting liquid biopsy-based assays for solid tumor types such as colorectal, lung, and breast cancer. Because liquid biopsy relies on a simple blood draw rather than invasive tissue sampling, it offers a scalable path to broader MRD adoption as a routine monitoring tool. Successful commercialization of solid-tumor MRD assays represents a substantial opportunity for diagnostic companies to expand their addressable market well beyond current hematologic-malignancy applications.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/minimal-residual-disease-market 

Emerging Market Trend: Growing Integration of Artificial Intelligence in MRD Analysis

Diagnostic companies are increasingly incorporating artificial intelligence into MRD workflows to accelerate interpretation of complex genomic and flow cytometry datasets. AI tools help identify subtle cancer-related signals that are difficult to detect manually, support faster analysis of NGS output, and enable machine-learning-based relapse-risk prediction from MRD results combined with patient data. This automation is expected to reduce laboratory workload and improve testing efficiency, positioning AI-enabled platforms as a key differentiator among MRD test developers going forward.

Market Challenge: High Cost Involved in MRD Testing

MRD assays require sophisticated instrumentation and specialized personnel, making the procedures costly and often requiring serial testing over a patient's treatment course, which compounds total expense. This cost burden limits accessibility in low-income economies lacking advanced digital and laboratory infrastructure, while smaller hospitals and diagnostic labs may struggle to justify the capital investment needed to adopt PCR- or NGS-based platforms. Compounded by inconsistent reimbursement policies across insurers and geographies, high testing costs remain a persistent restraint on broader MRD market penetration.

How Is Market Segmentation Done?

The research gives an in-depth segmental analysis of the minimal residual disease (MRD) industry. The segmentation in the market has been done on the basis of detection target, test technique, end user, and region. By detection target, the market spans Lymphoma, Leukemia, Solid Tumors, Multiple Myeloma, and Others; by test technique, it covers Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), and Others; and by end user, the market includes Hospitals and Specialty Clinics and Laboratory Centres. This research assesses the contribution of each segment and pinpoints the segments driving the present-day demand and those that will grow strongly during the forecast period. This analysis helps stakeholders analyze evolving demand trends and recognize promising market opportunities.

Which Region Leads Market Demand?

The report includes a regional analysis of the minimal residual disease (MRD) market, covering North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the overall market, attributed to strong patient and physician awareness of MRD testing benefits, widespread adoption of advanced screening technologies, and ongoing initiatives such as the January 2025 partnership between Adaptive Biotechnologies and NeoGenomics to expand access to personalized blood-cancer monitoring. Further, Asia Pacific is expected to witness significant growth during the forecast period, influenced by a rising burden of hematologic cancers linked to changing lifestyles and aging populations, improving diagnostic capabilities, and rapid growth in markets such as India, where expanding diagnostic infrastructure and genomic testing capacity are accelerating adoption. In addition to this, there is an analysis of regional demand, investments, infrastructure, regulatory environment, technology penetration, and industry development.

Who Are the Key Market Players?

The report presents a detailed competitive analysis of the minimal residual disease (MRD) industry. Player positioning and their strategy, such as new product/service launches, partnerships, mergers and acquisitions, geographic expansion, capacity expansion, technological developments, etc., have been analyzed. The report also examines the competitive structure of the industry and how organizations are responding to changing consumer demands.

A few of the key players in the market include:

Adaptive Biotechnologies; ArcherDX; ARUP Laboratories; Asuragen; Bio-Rad Laboratories; Cergentis; F. Hoffmann-La Roche Ltd.; Genetron Health; GRAIL, LLC; Guardant Health; ICON plc (MolecularMD); Inivata; Invivoscribe; Mission Bio; Natera; NeoGenomics Laboratories; Opko Health; QIAGEN; Quest Diagnostics; and Sysmex Corporation, among others.

Future Outlook

The minimal residual disease (MRD) market is projected to grow and evolve until the forecast year 2034 as demand grows, applications widen, and industry players respond to changing demands. Innovations, investments, and technological advancements are expected to drive market development and present new opportunities in major segments and geographies. This report provides insights into how the market is expected to evolve, thereby enabling stakeholders to understand opportunities and developments likely to shape the market during the forecast period.

More Trending Latest Reports By Polaris Market Research:

top-resin-manufacturers-across-the-global-market

a2-or-regular-milk-what-us-consumers-are-choosing-in-2025

probiotic-and-prebiotic-soda-market

food-safety-testing-market

transcatheter-aortic-valve-replacement-tavr-market

energy-engineering-service-outsourcing-eso-market

healthcare-industry-market-research

latest-innovations-in-cardiac-pacemakers-market-that-save-lives

adtech-market